In new research, scientists at the Department of Energy's SLAC National Accelerator Laboratory, in collaboration with ...

NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC (Olatec), a leader in the developing class of oral selective NLRP3 inhibitors, today announced a publication in Cancer Research Communications ...

Specifically, in the in vivo peritonitis model, ISM5059 demonstrated a robust, dose-dependent inhibition of Interleukin-1β (IL-1β), a potent pro-inflammatory cytokine as a master regulator of the ...

Wound healing is a multistep biological process involving inflammation, tissue formation, and remodeling. While inflammation is essential for clearing debris and recruiting repair cells, excessive or ...

An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support ...

Artificial-intelligence-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibitor ...

Whether a person eats a cookie or devours the whole box could come down to the mood of microglia in their hypothalamus. Blocking activation of the region’s NLRP3 inflammasome could keep excessive ...

Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, ...

BioAge Labs, Inc. announced progress in their development pipeline, highlighting the advancement of their oral NLRP3 inhibitor BGE-102, with initial clinical data expected in the second half of 2025.

In a recent study published in Scientific Reports, researchers described the preclinical profile of JT002, a novel and orally bioavailable small molecule inhibitor of the NLR family pyrin ...